Investigation of efficacy and safety of basal supported oral therapy by alternate-day insulin degludec injectio
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000010885
- Lead Sponsor
- Juntendo University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
1)Patients with past medical history of hypersensitivity to Degludec 2)Patients with hypoglycemia 3)Patients with serious liver,renal, pituitary and adrenal insufficiency. Patients with diarrhea, vomiting and other gastrointestinal problems. Patients with starvation state or unstable appetite. 4)Patients with serious diabetic complications including proliferative retinopathy (except for stable condition by photocoagulation). 5)Patients who are pregnant, hope to be pregnant, or are in lactation period. 6)Judged as ineligible by clinical investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of HbA1c and fasting glucose levels from baseline
- Secondary Outcome Measures
Name Time Method Daily glucose profile by SMBG Frequency and severity of hypoglycemia and other adverse events
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.